At www.muckety.com, Dr. Lindsay Rosenwald’s relationship to the Republican Jewish Coalition and Paramount Capital Asset Management, Inc. is visually illustrated in a diagram-like map.

www.youtube.com/watch?v=s485sqUgSzc

Dr. Lindsay Rosenwald has a profile on Wellness.com that displays his education, current practice, and services offered.  He is a graduate of Temple University Medical School, and he presently works as a general practitioner in New York City.  As a general practitioner, Dr. Lindsay Rosenwald provides an array of services which include bone density testing, immunizations, physical examinations, and stress reduction plans.

The NyICECATS have recognized Dr. Lindsay Rosenwald on multiple occasions as an exceptional member of the organization’s adult team.  The NyICECATS is a Jewish Orthodox youth hockey organization that has branched out to adults.  At both the third and fourth annual Captain’s Dinner, held on March 12^th at Le Marais in New York City, Dr. Lindsay Rosenwald was honored and presented with gifts by Neil Herskowitz, who is the Director of Manhattan Pharmaceutical, Inc.  The gifts of team included a Bauers 190.  As the night went on, Dr. Lindsay Rosenwald made an announcement that he was committed to playing hockey at the Piers for 25 more years.  The dinner concluded with the “Golden Balls” award ceremony.

A search for Dr. Lindsay Rosenwald in the Huffington Post’s FundRace of 2008 displays his donation to the McCain Victory Committee of $61,800.

Paramount BioScienses’ Plan

Not only can Paramount BioSciences offer specialized services and support, but is additionally involved in new product development, biotech organizations purchase and development. It helps the freshly built businesses in several value-adding methods. They will evaluate system candidates for the companies; generate progression strategies to facilitate the growth process prior to, in the course of, as well as following the configuration of Portfolio Firms. Equally, back-up and know-how is fully recognized by BioSciences as it allows its Portfolio Businesses to access to much more experienced infrastructure than they might have. This gives the business management to pay attention to the medicine candidates’ development as opposed to constructing their very own infrastructure. In lots of ways, this kind of design produced by Paramount’s founder Lindsay Rosenwald gives both expert and “back office” support and limits delays in the advancement process, as well as maximized the earnings for Portfolio companies and the client community.

Right after acceptance and in-licensing, a dedicated supervision crew through the complete creation step generally looks after pharmaceutical candidates. Senior medication production personnel at Paramount BioSciences, including Lindsay Rosenwald, facilitate Portfolio Firms in all of the areas of growth. This includes formulation, medical improvement, toxicology, production, quality assurance, and commercialization. Using their extensive working experience in developing top drug solutions, the Paramount’s team provides solutions for an assortment of therapeutically signs, beginning with inflammation to cardiovascular to oncology to neurology and several other hints. Global network of professionals as well as industry frontrunners within the healthcare and research communities provide guidance throughout the candidates’ creation and approval cycle.

Along with an established track record, Paramount BioSciences facilitates Portfolio Corporations hire employees that will guide the new businesses formed around the new compounds. On the list of recent employees at Portfolio Organizations, there are such executives as the previous CEOs of Roche, Biogen, Johnson&Johnson, Amgen and many more.

More than twenty years of financing and progression of biomedical organizations across a wide range of therapeutic indications, Lindsay Rosenwald is head of Paramount BioSciences’ more than 40 biotech organizations. He forms businesses from the ground-up employing his very own cash and then funds are raised from numerous non-public individuals through Paramount Capital.

Paramount handles such important features as human resources, legal, market analysis, economic capabilities. This assists its Portfolio firms to focus on medical research and generating value for shareholders, licensors and patients.

With such a keen eye for locating and constructing progressive medicines, Paramount BioSciences evaluates the quality and promises of drug candidates around the world, from tiny biotech organizations and instructional centres to substantial prescription companies.

Paramount Approach To Value Generation

What makes Paramount BioSciences stand out is that their infrastructure and outer network enables them to help Paramount Incubated Firms right up until they become self-sufficient. The creation period has been developed by Lindsay Rosenwald in 1999 and may be described in a simple pattern much like this one:

Product Property –> Paramount Preliminary Funding and Development –> Incubation –> Portfolio Company Formation –> Cost Inflection Point

Staff for every single Portfolio Business is appointed in agreement with developmental and financial situations. On average, the majorities of workers at Paramount have at least 15 years of experience in biotechnology or medical care industries driving drug applicants through the regulatory and clinical value string. Their expertise ranges from molecular biology to clinical treatments.

With such a serious practical experience across the pharmaceutical creation enterprise, Lindsay Rosenwald has been able to produce the team with leadership roles within the biotech market with numerous pharmaceutical drug products being sold globally, including Viracept, Neulasta, Rituxan, and Kepivance.

Paramount Departments

Paramount Biosciences

With over forty personnel in eight offices globally, Paramount BioSciences compete and bargain for college and business biotechnology entitlements. It develops and in-licenses compounds for numerous restorative signs – from inflammation and cardiology to neurology and cancer. Lindsay Rosenwald helps create standalone biotech corporations that can attract money and succeed as publicly traded firms

Paramount BioCapital, Inc.

Paramount BioCapital Inc. is a NASD-registered dealer that collects capital for the Portfolio Organizations. It raised in excess of $1 billion and around $200 million in 2009. Using their extensive knowledge in investments purchases such as “PIPEs”, reverse takeovers, self-registrations and private placements, Paramount BioCapital is now the leader in the biotechnology capital sector.

Paramount Development

Lindsay Rosenwald operates directly with Paramount Corporate Development, which is involved with in-licensing and narcotic creation activities. The Business Development group contains twenty market veterans with a huge expertise in all facets of pharmaceutical advancement, including formulation, clinical procedures, manufacturing and commercialization.

Paramount BioCapital Asset Management

Property Management is responsible for acquiring and distributing equities of global healthcare organizations. It has an established hedge fund construction and assets under management in numerous private positioning vehicles.

Paramount Acquisition Company

Paramount Acquisition Company creates special equity finance products that match good sized capitals with late-stage non-public firms. It recently declared a $54 million purchase with Valeritas, which is a health-related device business with its principal FDA-approved insulin pump h-Patch.

Paramount BioSciences Executive Management Staff

Normally, Paramount BioSciences workers have got 15 years of strong knowledge in the medical and regulating functions. Headed by Lindsay Rosenwald, the team members participated in a large number of prescription creation and commercialization projects, including Rituxan, Viracept, Sutent, and Neulasta. Far more than 50 compounds presently go through medical development procedure and the products include medicines across a vast range of indications that include neurological diseases, metabolic problems, contagious diseases and cancer.

Lindsay A. Rosenwald, M.D., is CEO and Chairman at Paramount BioSciences. His considerable expertise within biotechnology, pharmacology and finance made him one of the market leaders in the biotechnology and life sciences industries. With more than 20 years of working experience in building and investing in biotechnology and life science businesses, Dr. Lindsay Rosenwald created and nurtured more than 40 biotech/pharma businesses.

J. Jay Lobell, J.D., is President and Chief Operating Officer at Paramount BioSciences. His prior practical knowledge includes collaboration at Covington & Burling, where he supplied economic, regulatory, business, and litigation assistance to financial institutions, corporations and individuals.

Benefits of Paramount BioSciences Model

What makes Paramount BioSciences a desired acquirer of drug treatments and developer of biotechnologies is that Lindsay Rosenwald’s team of developers along a global business development team that assesses and facilitates unit and marketplace options. The offices of Paramount BioSciences are situated worldwide, which includes New York City, London, Boston, Shanghai, San Diego, North Carolina, Orange County (California)). Promising medication candidates are migrated forward rapidly in the certification process. Reps of all areas in drug creation cycle work together to make sure an agreement to move ahead. The next thing is the generation of unit development plans for the compound and hiring supervision personnel. At this time, the chemical substances are usually transferred to Portfolio Companies with no transition hold-up. The product candidates are supported through the specialized medical and regulatory system.

Paramount BioSciences has proved to rapidly perform deals and initiate development work. Its access to money is a crucial part of any product development. It offers Portfolio organizations with the framework that promotes drug candidate’s acceleration through to marketplace, removing odds of program getting stalled.

Clinical and commercial expertise at the company stage assists Paramount Portfolio companies increase value to in-licensed products.

History regarding Financial Wherewithal

Paramount BioSciences under the direction of Lindsay Rosenwald has produced over $1 billion from outside people in addition to their own investment in Paramount’s portfolio organizations. All companies and specialized medical studies funded through the organization get substantial funding on all stages of the creation cycle.

Linsay Rosenwald has regular and close interaction with the leading US sell-side and buy-side organizations that consist of notable health care individuals, with whom Paramount’s hedge funds put money into the deals not directly involving this company by itself. Paramount’s staff has real-time perception of health-related capital markets, which resulted in over $400 million funds for Portfolio Corporations in 2009 year alone, including $200 million by Paramount. This includes $47 million for Cougar Biosciences along with SG Cowen, $37 million for Ziopharm Oncology, $22 MM for Chelsea Therapeutics and $16 million for Innovive Pharmaceuticals. Many of the top health care funds financed in Paramount in 2010, which continues to be a good indication for the development of medical and life sciences industries.

Dr. Lindsay Rosenwald’s researches related to Paramount Group of Companies is also responsible for introducing many companies like Paramount BioCapital which is the one invested for many new budding companies, Paramount BioSciences which is the one became the start of the companies related to the science of Biotechnology, Paramount Capital Asset Management the one responsible for the improvements regarding the employees nature and their efforts to increase the number of achievements in the research fields, Paramount Capital Investment this company can be said to be the one which helped many of the new fresh companies towards the financial matters and also the one which were weak at their financial status. This is how Dr. Lindsay Rosenwald took care of many companies from being disintegrated from their goals and objectives.

Industries like investment banking, venture capital, asset management and direct investing are the said to be the branches of the Paramount Group of Companies which help them to support any companies which are at their initial stages. By this it can be said that the undertakings of the Dr. Lindsay Rosenwald was of his keen interest to his starting and there many followers of him in this field.

Dr. Lindsay Rosenwald can also be known to start companies which were the inventories to the new drugs that help the human life a lot by curing the diseases that affect human body by making them weak. Cougar Biotechnology and Polarx Biopharmaceuticals are the two most popularly known companies under the foundation of Rosenwald. These two companies invented two new drugs in addition to the older ones. Though these drugs are being developed by the companies under Rosenwald’s guidance they are being allowed to enter the market after few medical tests. Drugs are the one which are known scientifically as life Savers.

All the inventions and developments of the drugs are done by highly qualified people related to various fields of Biotechnology under scientific research. It can be said that the team is grouped in accordance to the experts who are highly skilled with the practical and theoretical knowledge. The formulation of the drug and its manufacturing are done in a process like technology transfer, pharmacology and toxicology aspects of the drug, clinical development, regulatory, marketing, etc. The sacrifices of these team members are valued with the success selling of their products in the market.

It is Dr. Lindsay Rosenwald who balanced the financial status of many companies with the help of Paramount BioCapital. He was a person by whom many new young Biotechnologists where inspired and laid new ways to further success. Drugs under Rosenwald’s foundation helped to cure more deadly diseases which can be thought as the one having no treatment. It is the Paramount BioSciences which invented such new drugs to cure such deadly diseases. Rosenwald was the one with two invaluable features which were both as per financial and physician analysts.

Dr. Lindsay Rosenwald reputed himself as a corporate finance managing director for D.H. Blair & Company, in the year of 1988. This was a privately owned investment based business. There, he was the leader of a team of three physician-financiers that sought through the medical community for any new and profitable break-through that could make use of private investment. They located various schools of medicine, universities, hospitals, drug companies, study groups, and scientific firms. Dr. Lindsay Rosenwald then was able to found Paramount BioCapital in 1991. Here, he worked within the biotechnology and bioresearch disciplines. He became a NASD-member dealer in 1992 and established the investment and merchant bank named Paramount Capital Investments LLC, in 1995. Owned by Dr. Lindsay A. Rosenwald, the Paramount Capital Asset Management organization has managed investments from a number of assets since 1994 that have a concentration in the biotechnology and other technological spheres. Dr. Rosenwald serves on the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was ranked number one in the list of 100 Molecular Millionaires with a worth of $617,721,671. Dr. Lindsay Rosenwald operated on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He quit in order to contribute additional time performing in the biotechnology market. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another business that was first founded by Dr. Rosenwald and was originated completely on abiraterone acetate. Abiraterone Acetate, even though it had not yet attained phase III in clinical testing trials, was showing so much potential in the therapy and management for prostate cancer that Johnson & Johnson offered a short-term unification bid and procurement  for the Cougar Biotechnology corporation for $1 billion. Dr. Lindsay Rosenwald, apart from the scores of ventures which have imparted financing and resources to portfolio companies, has also began the Rosenwald Foundation. This is a nonprofit outfit that has been triumphant in offering millions of dollars in aid of many medical and scientific instruction institutions.

Rosenwald graduated from Abington High School in Pennsylvania in 1973. He went on to attend Penn State University and graduated as a part of the Betta Gamma Sigma business school honor society in 1977, having received his degree in finance. He then attended Temple University’s School of Medicine where he receive his doctorate in 1983. He began work in Abington Medical Hospital but started a private practice soon thereafter. Taking his abilities from his private practice to Wall Street, Lindsay Rosenwald began using both finance specialization and his unique insights into the medical industry to work in an advisory capacity. This would become the foundation of the work for which he is best known.

After five years on Wall Street, Lindsay Rosenwald established the beginnings of the Paramount Group, including Paramount BioSciences and Paramount BioCapital, both founded in 1991 in order to provide a unique and effective structure to assist in locating and supporting new bioresearch and biotechnology companies that showed significant potential. The Paramount Group includes more than just these two major strands, however. It is a collection of major support pillars that help new groups gain a secure place in the market and overcome the challenges of starting out as a biorearch company. While Paramount BioSciences helps to locate the companies which show the most novel ideas and the most promising research, Paramount BioCapital helps gain the needed resources to fund them. Paramount BioCapital has raised just short of a billion dollars for its portfolio companies over the last two decades.

Paramount Corporate Development then helps these companies (once they have been located ans supported) by assisting them in making effective corporate plans, business strategies, and provide basic business and strategic support. These landmark companies have all been a significant part of Lindsay Rosenwald‘s contribution to the industry, and are behind his widely acknowledged reputation as one of the forerunners in the biomedical industry, both as a contributor, entrepreneur, and developer. Over the last two decades, repeated success has solidified this reputation. The companies that he has established, developed, or invested in, have had an immense impact on the industry as a whole. The contributions have not only been financially successfully, but revolutionary in the industry, making significant progress in treatment for prostate cancer, leukemia, dense tumors, and more. Lindsay Rosenwald and his contributions do not seem to be waning. Rather, over the last three years, we have seen a significant increase in the number of investments made. The innumerable accomplishments that Lindsay Rosenwald’s work has led to in the biotechnology and bioresearch fields include a few notable highlights. One of the portfolio companies of the Paramount group received the fastest approval time from the Food and Drug Administration that we have seen to date. From a financial perspective, we have seen major success, with notable examples like Sanctura – a company developed by the Paramount Group which sold for approximately $600 million. The impact on the medical field itself, with astonishing progress in areas like leukemia, tumor, and cancer treatment, are just a few of the more significant items of note. The acquisitions from outside companies may be one of the greatest signals of how successful Lindsay Rosenwald has been. Groups like Johnson & Johnson, Albany Molecular, and Myriad Pharmaceuticals, have acquired portfolio companies developed by the Paramount Group, and the total cost of acquisitions have exceed $1 billion. All of this success may root back to the double disciplines that Lindsay Rosenwald chose to pursue.

Having experience in both the financial sector and in medicine and biotechnology, Lindsay Rosenwald has been able to offer insights that are matched by few others in the history of modern healthcare. He is not only able to seek out those companies which show great potential, he is also able to accurately foresee the challenges they may face, and prepare them with resources and strategies to cope with those challenges successfully. In addition to real financial success for both himself, the Paramount Group, and his portfolio companies, Lindsay Rosenwald has selflessly established the Rosenwald foundation. This nonprofit organization has contributed millions of dollars to medical education institutions and other scientific communities, laying the groundwork for the revolutionary advances of the future. Lindsay Rosenwald has many accomplishments that he can successfully claim. He is the founder of the Paramount Group – a company which has led to some of the greatest pharmaceutical and biotechnology advancements over the last two decades. He is a successful entrepreneur and forerunner in the finance industry. His dual disciplines in finance and medicine have allowed him to have an impact that few others have had in the history of biomedicine, and in recent years, Lindsay Rosenwald is widely seen as the greatest contributor to the industry.

www.youtube.com/watch?v=rZI3tAvqa1o

Paramount BioSciences, LLC, founded and managed by Dr. Lindsay A. Rosenwald, is focused on the in-licensing of novel therapeutic and other medical technologies and is involved in corporate companies incubation and governance as well as business development. It extensively supports infrastructure with the experience in licensing, corporate development, clinical operations, and navigation of regulatory pathways. Paramount BioCapital, Inc., a FINRA registered broker-dealer, is involved in raising capital for Paramount’s Portfolio Companies.

Paramount BioSciences Executive Leadership Team

Paramount BioSciences executive team has an extensive collective experience in biotechnology/pharmacy and financial operations.

Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, Founder of Paramount BioSciences. With over 20 years of experience in developing, financing, and investing in biotechnology and life science companies, Dr. Rosenwald has made a powerful contribution to the today’s biotechnology sector. He has also established a charitable foundation called The Rosenwald Foundation Inc., which deals with educational philanthropic research.

J. Jay Lobell, J.D., President and Chief Operating Officer, was a former partner at law firm Covington & Burling, where he provided business, litigation, and regulatory advice to financial institutions, corporations, and individuals.

Russell Ellison, M.D., Executive Vice President, has almost 30 years of senior management pharmaceutical experience in commercialization and drug development. His former positions as the Vice President of Clinical Development at Fibrogen, Inc. and the U.S. Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, USA prove his ability to successfully deal with complex financial and management operations.

Advantages of Paramount BioSciences Model

What makes Paramount BioScienses the preferred acquirer of drugs and development is their flexibility on structure of collaboration and licensing. They have all the assets and skills to rapidly execute, deal and begin development work and access to the capital necessary to develop new products. With a huge clinical and commercial experience and expertise, Paramount’s mission is to maximize value to in-licensed products. Portfolio Companies can be focused on the development of a few key products by providing committed resources (human and financial) as well as a top-tier management expertise, which is focused on a specific product or field.

The structure of Portfolio Company fosters the compound’s progression through to market, eliminating possibilities of the program being shelved.

Financing Models and Related Information

In the past, Paramount Portfolio Companies were publicly traded, via initial public offering, acquisition, reverse merger, or self-registration. The following models are now employed: partnership, merger and acquisition, as well as the Private Company model.

In addition to its own investment in Portfolio Companies, Paramount Group has also raised substantial capital from outside investors. Over the past 60 months more than $400 million was raised for Paramount companies. Such companies include Ziopharm Oncology ($37MM), Cougar Biosciences ($47MM; in conjunction with SG Cowen), and Chelsea Therapeutics ($22MM).

Dr. Lindsay Rosenwald has been able to attract experienced CEO and management staff from such companies and organizations as Serono, Pfizer, Genentech, Johnson & Johnson, Roche, Biogen Idec, Sanofi Aventis, Antigenics, and Celltech. This ensures that Paramount’s commercial and financial aspects always stay on top level.

Clinical Assets of Selected Public and Private Companies Funded by Paramount BioSciences

Keryx Biopharmaceuticals: Phase II Phosphate binder; Phase II drug (Perifosine) for oncology; Phase II drug for oncology (UCN-01)

Javelin Pharmaceuticals: Phase III drug Intranasal Morphine and Intranasal Ketamine for pain relief; Pre-MAA and Phase III Injectable Diclofenac

Cougar Biotechnology: Phase III drug (Abiraterone Acetate) for prostate cancer; Phase I/II drug (Noscapine) for NHL; Phase II drug (Seocalcitol) for prostate cancer

Ziopharm Oncology: Phase II/III drug for myeloma; Phase I/II drug for sarcoma; Phase II drug for breast cancer

Hana Biosciences: Phase II/III drug for hematological malignancies; Phase I drug for EGFR inhibitor rash; Phase II anti-folate for oncology; Phase I/II camptothecin for oncology

Manhattan Pharmaceuticals: Phase II/III drug for Atopic Dermatitis; Phase III sedative buccal spray; Phase III topical head lice preparation

Chelsea Therapeutics: Phase III drug for orthostatic hypotension; Phase II drug for rheumatoid arthritis; IND stage drug for inflammatory conditions

NovaDel Pharma: Buccal spray platform technology; buccal sprays for migraine, anxiety, sleep and multiple other indications under development

Vioquest Pharmaceuticals: Phase II AKT inhibitor for solid tumors and hematological malignancies; Pre-NDA compound for Leishmaniasis; Phase II PTP inhibitor for multiple tumor types; Phase II drug for chemo-induced Hand Foot Syndrome

Tracon Pharmaceuticals, Inc.: TRC-105: Anti-CD105 monoclonal antibody addressing major cancers (prostate, breast and renal cell); TRC-93: Humanized, affinity-matured IgG and retained specificity of murine parental IgM HUI77. This antibody is active in combination with chemotherapy. TRC-102: Small molecule inhibitor of base-excision repair, shown to reverse Temodar® resistance without added toxicity

Alacrity BioSciences, Inc.: ALTY-0501: 0.025% doxycycline inhibits MMP-9 breakdown of corneal barrier. This is a novel mechanism approach to the $500 MM+ dry eye market, which currently offers limited treatment options. ALTY-0601: Small peptide therapeutic with a unique mechanism of action to reduce intraocular pressure (IOP) in patients with ocular hypertension or primary open angle glaucoma

Cutanea Life Sciences, Inc.: CLS001: Omiganan pentahydrochloride is a patented, novel peptide used to treat rosacea that has demonstrated activity against a wide variety of microorganisms, including gram-positive and gram- negative bacteria and fungi. CLS002: Next generation injectible chitosan in soft tissue augmentation. CLS003: Ionic Contra Viral Therapy in development for the treatment of cutaneous warts.

Ventrus BioSciences, Inc.: VEN309: New chemical entity for the topical treatment of hemorrhoids; mechanism of action is to inhibit venous contraction and platelet aggregation, allowing normalization of blood flow. VEN307: Diltiazem cream for anal fissures. VEN308: Phenylephrine gel for fecal incontinence.

Mt Cook Pharma, Inc.: MCP101: TRPV1-agonist; an intravesical treatment for overactive bladder (OAB) and benign prostate hyperplasia (BPH) patients who fail oral medications. MCP202: Oral, first-line delta receptor agonist treatment for OAB and BPH. MCP201: Chemically novel, injectible, mixed opioid receptor agonist for serious pain

Indigo Pharmaceuticals, Inc.: INDI-702: Synthetically derived, oral small molecule for large, chronic, cardiovascular market. Possesses both phosphodiesterase (PDE) inhibitor activity and thromboxane A2 synthetase (TxA2) inhibitor activity and demonstrated increase in peak walking time (p=0.004) compared to placebo at 24 weeks.

Coronado BioSciences, Inc.: CNDO101 (5-imino-3-deoxydoxorubicin): Rationally designed anthracycline analogue with safety advantages – Structural elements responsible for cardio-toxicity has been eliminated. CNDO102 (NK cell activator): Immunotherapy targeting minimal residual disease. The compound has already shown positive efficacy in its ongoing Phase 1 Trial. CNDO103 (Bcl-2 family protein inhibitor platform): Rationally designed, pan-Bcl-2 inhibitor with multiple oncology applications.

Should there be doubt of these unique traits, simply observe how the Rosenwalds parent.  Not content to simply support charities in an offhand or sidelined way, they have made it a part of their home life.  They hold various fund raisers and events centered around several organizations focusing on children with the aim of setting an example and providing a path for their children to follow.  In taking a look at the big-picture of various platforms they support, it becomes clear that the Rosenwalds are primarily and daily concerned with bettering the future of mankind.  Their efforts focus on programs and institutions concerned with societal improvement with a strong focus on education.  It’s increasingly uncommon to find individuals who not only simply donate to groups around the world, but also foster direct relationships with many individuals in need.

One does not need to search far to hear a story or two about Dr. Lindsay Rosenwald’s generosity.  An example would be an artist who, through sponsorship by Lindsay Rosenwald, has found their paintings to be hanging at the Institute’s headquarters.  Although spectacular in their own right, Lindsay Rosenwald bought the paintings solely to assist the painter.  The Rosenwalds were also honored at one of Sh’or Yoshuv’s previous events.  Reluctantly accepting the award, Lindsay Rosenwald stated, “I don’t like the lime light, but you know I will do what it takes to help you.”

The most telling account centers around a time when the Institute was in a very dire budget crisis.  Dr. Lindsay Rosenwald held a meeting in his home to resolve this issue.  Holding his silence through the entire meeting, Lindsay Rosenwald then approached the Rabbi and quietly assured him that he would front the shortfall in while.  He was sensitive to the fact that the room was full of people, and required no personal lauding for his generosity.

The Institute has proudly dedicated its campus atrium to Mr. David R. Rosenwald, Esquire, Lindsay Rosenwald’s late father.  As personal friends to Sh’or Yoshuv Institute, the Rosenwalds participate in the High Holy Days and a multitude of other spiritual services.  With a lasting and true commitment to their background, the Rosenwalds are irrevocably a part of the solid base that keep the Institute going as a unique hub of Jewish Education.

On the day of the interview, I was escorted into Lindsay Rosenwald’s office where I  sat office for about six hours:  talking occasionally, watching him take multiple calls at once, handle an endless round of visitors and calmly direct trades as he observed the market from any one of the four terminals showing market activity.   At the end of the day, he told me I was hired, and that I should come back in the morning to discuss details.

That evening, I remember calling my brother, Tom, and telling him about my day.   He shouted through the phone:  “You met with who?!    Do you have any idea who Lindsay Rosenwald is?!!!”

To say it was a meeting that changed my life forever, would at best be an understatement.

Lindsay gave me an opportunity that I would bet no one or at best very few would have given me.     I was media-regular, offering nutritional advice with no understanding whatsoever of the public markets.   Yet, still, Lindsay Rosenwald took a chance and introduced me  to the world of venture capital, merchant banking, public companies and financing.    It was a fascinating, hockey-stick learning experience that was intense, exciting, and life-changing.

Although I only stayed at Paramount for about a year, that experience along with a healthy boost of encouragement and three clients from Lindsay enabled me to start my firm The Investor Relations Group.

Today, I am eternally grateful to Lindsay.   I consider him both a mentor and friend.  In a most informal way, he taught me valuable lessons that I cite regularly;

Pick a direction and stay focused.

Pioneers get the arrows, settlers get the land.

It is better to own 10% of the goldmine, than 100% of the shaft.

Don’t worry about idle gossip if its about you…it is really idol worship.

Lindsay is smart.    He works hard.   He is relentless.    I admire those traits.     But mostly, I will never forget that just as he chose me to join Paramount—in so many ways the least likely candidate  for the job—he sees potential in things that most people simply miss.    He nurtures that potential.    He provides the environment to develop technologies and for people to think, grow, reach, expand, create and try.
Whether he is acknowledged and thanked for it, Lindsay single-handedly launched more successful careers than I can count.    We all had talent.    But whether we choose to admit it or not, we often come to our own greatness by the unselfish, helping hands of others.     To so many, Lindsay has been that helping hand:   to me starting an investor relations firm, to those who launched funds, and to the countless public companies that he created which in turn offered both jobs and opportunities.

The companies represented and assisted by Paramount have over 40 products that are moving through clinical trials. Paramount also has a notable track record on concerns related to scientific, industrial, health, and safety issues in these fields.

Dr. Linsday A Rosenwald founded Paramount BioSciences, LLC to focus on licensing of groundbreaking treatments and other medical technologies.  Paramount BioSciences also assists companies in their incubation, governance, and business development efforts. It greatly supports corporate infrastructure, and utilizes its vast history in licensing, development, clinical operations, and regulatory issues. Paramount BioCapital is a registered broker-dealer with FINRA, and mainly focuses on generating funding for Paramount’s Portfolio Companies.

The executive management team at Paramount BioSciences has extensive experience in biotech, pharmaceutics, and financial operations.

Lindsay A. Rosenwald, M.D. serves as the Chairman, Chief Executive Officer, and Founder of Paramount BioSciences. With over experience spanning twenty years two decades’ experience in the development, financing, and investment in biotech and life science firms, Dr. Lindsay Rosenwald has made a remarkable contribution to today’s biotechnology field. Lindsay Rosenwald also established a nonprofit charity, The Rosenwald Foundation Inc., which focuses on educational philanthropic research.

J. Jay Lobell, J.D. is the President and Chief Operating Officer.  He came to Paramount in New York after serving as a  partner at law firm Covington & Burling.  This background gave him vast experience in providing business, legal, and regulatory advice to financial institutions, corporations, and individuals.

Russell Ellison, M.D. serves as the Executive Vice President.  Dr. Ellison has almost three decades’ worth of experience in senior management pharmaceuticals, specifically in commercialization and drug research and development. Formerly, he served as VP of Clinical Development at Fibrogen, Inc., as well as the US Vice President of Medical Affairs and Chief Medical Officer at Sanofi-Synthelabo, New York USA.  This extensive background proves his ability to successfully manage complex financial and corporate operations.

Dr. Linsday A Rosenwald began Paramount by founding Paramount BioSciences, LLC, which focuses on assisting in the licensing of the latest therapies and other pharma technologies.  Paramount BioSciences also works with companies to assist in incubation, corporate governance, and corporate development. Through Paramount BioSciences, and Lindsay Rosenwald’s extensive background in finance and medicine, The Portfolio Group of Companies are provided with support in corporate infrastructure.  Paramount utilizes its functions in licensing, development, clinical operations, and regulatory concerns to assist these companies.  Also of note is Lindsay Rosenwald’s Paramount BioCapital, Inc., a FINRA registered broker-dealer that focuses on raising and generating funding for Paramount’s Portfolio Companies.

The executive management team at Paramount has an inclusive background in biotechnology, pharmaceuticals, and finance.

Lindsay A. Rosenwald, M.D. is the Chairman and CEO as well as the Founder of Paramount BioSciences. Lindsay Rosenwald has over twenty years’ background in the research and financing in biotechnology and life science firms.  Lindsay Rosenwald also founded the nonprofit organization The Rosenwald Foundation Inc., which works to benefit medical, educational, and philanthropic scientific research.

J. Jay Lobell, J.D. is the President and COO.  Arriving at Paramount after serving as a partner at law firm Covington & Burling, J. Jay Lobell’s background gave him useful experience in providing corporate, litigation, and regulatory guidance to financial institutions, businesses, and individuals.

Russell Ellison, M.D. is the Executive Vice President.  Dr. Ellison has almost thirty years’ worth of background in management and pharmaceutics, focusing on commercialization and pharmaceutical research and development. Previously he served as VP of Clinical Development at Fibrogen, Inc., and the US Vice President of Medical Affairs and Chief Medical Officer at Sanofi-Synthelabo, USA.  This experience proves his capabilities in successfully managing complex financial and corporate operations.